Journal of Nuclear Cardiology最新文献

英文中文

XTR003, a Fatty-acid Metabolism PET Tracer: A Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics in Healthy Volunteers.

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology

Pub Date : 2025-02-07 DOI: 10.1016/j.nuclcard.2025.102144

Tiantian Mou, Jingjing Meng, Chengyu Lin, Xiaofen Xie, Bailing Hsu, Xiaoli Zhang

Purpose: XTR003 is a novel ¹⁸F-labeled fatty-acid PET tracer to image myocardial fatty-acid metabolism that can be potentially used to assess myocardial viability for ischemic heart disease. This Phase I study evaluated its safety, biodistribution, radiation dosimetry, and pharmacokinetics.

Methods: Ten healthy Chinese volunteers (mean age of 28.4±4.6 years, 3 females) were intravenously injected with XTR003 (296-370 MBq) at rest and monitored for adverse events on the day of injection and follow-up days. Multiple whole-body PET images were acquired within 290 minutes and processed to investigate the biodistribution and radiation dosimetry. Whole blood, plasma, and urine were collected simultaneously for 420 minutes to evaluate the pharmacokinetics with the measurement of radioactivity.

Results: Only two treatment-related adverse events occurred with no severe adverse effects. After tracer injection, XTR003 in the plasma peaked at 2.883 min as 0.0108235 percentage of injected dose per gram (%ID/g) and reduced to the minimum at 30 min. The 0-20 min whole-body PET images indicated that both heart and liver were two critical organs with the highest percentage of injected dose (%ID) (4.37±0.66 and 48.76±4.17 %ID). Specifically, XTR003 demonstrated high initial uptake in the heart, with sustained retention for up to 290 minutes (SUV: 6.50 ± 2.54 at 0-20 minutes and 5.89 ± 2.18 at 270-290 minutes). The whole-body effective radiation dose was 17μSv/MBq. The cumulative urinary excretion was 9.009%.

Conclusion: XTR003, as a ¹⁸F-labelled radiotracer, was safe and well-tolerated. The rapid uptake and prolonged retention of XTR003 in the heart show promise for evaluating myocardial fatty acid metabolism. The phase II clinical trial to explore the efficacy of XTR003 for detecting myocardial viability should be warranted.

Trail registration number: ClinicalTrials.gov Identifier: NCT05136391.

{"title":"XTR003, a Fatty-acid Metabolism PET Tracer: A Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics in Healthy Volunteers.","authors":"Tiantian Mou, Jingjing Meng, Chengyu Lin, Xiaofen Xie, Bailing Hsu, Xiaoli Zhang","doi":"10.1016/j.nuclcard.2025.102144","DOIUrl":"https://doi.org/10.1016/j.nuclcard.2025.102144","url":null,"abstract":"<p><strong>Purpose: </strong>XTR003 is a novel <sup>18</sup>F-labeled fatty-acid PET tracer to image myocardial fatty-acid metabolism that can be potentially used to assess myocardial viability for ischemic heart disease. This Phase I study evaluated its safety, biodistribution, radiation dosimetry, and pharmacokinetics.</p><p><strong>Methods: </strong>Ten healthy Chinese volunteers (mean age of 28.4±4.6 years, 3 females) were intravenously injected with XTR003 (296-370 MBq) at rest and monitored for adverse events on the day of injection and follow-up days. Multiple whole-body PET images were acquired within 290 minutes and processed to investigate the biodistribution and radiation dosimetry. Whole blood, plasma, and urine were collected simultaneously for 420 minutes to evaluate the pharmacokinetics with the measurement of radioactivity.</p><p><strong>Results: </strong>Only two treatment-related adverse events occurred with no severe adverse effects. After tracer injection, XTR003 in the plasma peaked at 2.883 min as 0.0108235 percentage of injected dose per gram (%ID/g) and reduced to the minimum at 30 min. The 0-20 min whole-body PET images indicated that both heart and liver were two critical organs with the highest percentage of injected dose (%ID) (4.37±0.66 and 48.76±4.17 %ID). Specifically, XTR003 demonstrated high initial uptake in the heart, with sustained retention for up to 290 minutes (SUV: 6.50 ± 2.54 at 0-20 minutes and 5.89 ± 2.18 at 270-290 minutes). The whole-body effective radiation dose was 17μSv/MBq. The cumulative urinary excretion was 9.009%.</p><p><strong>Conclusion: </strong>XTR003, as a <sup>18</sup>F-labelled radiotracer, was safe and well-tolerated. The rapid uptake and prolonged retention of XTR003 in the heart show promise for evaluating myocardial fatty acid metabolism. The phase II clinical trial to explore the efficacy of XTR003 for detecting myocardial viability should be warranted.</p><p><strong>Trail registration number: </strong>ClinicalTrials.gov Identifier: NCT05136391.</p>","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":" ","pages":"102144"},"PeriodicalIF":3.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is it solid enough? Diagnostic performance of solid-state detector technology without attenuation CT against invasive angiography.

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology

Pub Date : 2025-02-06 DOI: 10.1016/j.nuclcard.2025.102163

Attila Feher, Mouaz H Al-Mallah

引用次数: 0

Feasibility of the Absolute Quantification and Left Ventricular Segmentation of Cardiac Sympathetic Innervation in Wild-type Transthyretin Amyloidosis Cardiomyopathy with [¹²³I]-MIBG SPECT/CT: the I-NERVE study.

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology

Pub Date : 2025-02-03 DOI: 10.1016/j.nuclcard.2025.102146

Alwin Tubben, Niek H J Prakken, Oleksandra V Ivashchenko, Hendrea S A Tingen, Andor W J M Glaudemans, Walter Noordzij, Hans L A Nienhuis, Peter van der Meer, Riemer H J A Slart

Purpose: Cardiac sympathetic neuronal dysfunction is an early marker in wild-type transthyretin amyloidosis cardiomyopathy (ATTRwt-CM). [¹²³I]-MIBG imaging evaluates cardiac sympathetic innervation but lacks volumetric activity quantification in current methods. This study aims to quantify cardiac sympathetic neuronal dysfunction in ATTRwt-CM using [¹²³I]-MIBG SPECT/CT and correlate findings with functional and structural cardiac parameters from echocardiogram and cardiac magnetic resonance imaging (CMR).

Methods: We conducted a single-center, descriptive, cross-sectional study to quantify absolute myocardial sympathetic function in ATTRwt-CM using [¹²³I]-MIBG SPECT/CT. Retrospective reconstruction allowed for absolute tracer-uptake quantification of the left ventricle, overall and segmented, in kBq/mL, SUV and percentage of the injected dose (%ID). Echocardiography, CMR, and bone scintigraphy were performed according to clinical standards. Segmented [¹²³I]-MIBG SPECT/CT values were correlated with global longitudinal strain (GLSS) on echocardiography, native-T1, and extracellular volume (ECV) on CMR using SPECT/CT fused with CMR.

Results: Twenty-nine ATTRwt-CM patients (75.8±6.6 years, 90% male) were prospectively included. All exhibited cardiac sympathetic neuronal dysfunction, with a median late heart-to-mediastinum ratio of 1.69[1.45-1.89] and a washout rate of 22.7% (16.4-27.3%). SUV_mean, SUV_peak, SUV_max and %ID were 1.80 ± 0.78, 3.84 ± 1.41, 4.46 ± 1.68 and 0.46 ± 0.18 respectively, correlating with semi-quantitative [¹²³I]-MIBG measures. No correlations were found with GLSS on echocardiography or native T1 and ECV on CMR.

Conclusion: The current study demonstrates the feasibility of volumetric quantification of [¹²³I]-MIBG SPECT/CT in ATTRwt-CM. SUV_mean, SUV_peak, SUV_max and %ID correlate with semi-quantitative measures but not with key cardiac parameters on echocardiography or CMR. This confirms the sensitivity of [¹²³I]-MIBG SPECT/CT to different aspects of cardiac function or pathology.

Trial registration: EudraCT ref. 2020-003350-72, retrospectively registered 20 March 2023. https://classic.

Clinicaltrials: gov/ct2/show/NCT05776212.

{"title":"Feasibility of the Absolute Quantification and Left Ventricular Segmentation of Cardiac Sympathetic Innervation in Wild-type Transthyretin Amyloidosis Cardiomyopathy with [<sup>123</sup>I]-MIBG SPECT/CT: the I-NERVE study.","authors":"Alwin Tubben, Niek H J Prakken, Oleksandra V Ivashchenko, Hendrea S A Tingen, Andor W J M Glaudemans, Walter Noordzij, Hans L A Nienhuis, Peter van der Meer, Riemer H J A Slart","doi":"10.1016/j.nuclcard.2025.102146","DOIUrl":"https://doi.org/10.1016/j.nuclcard.2025.102146","url":null,"abstract":"<p><strong>Purpose: </strong>Cardiac sympathetic neuronal dysfunction is an early marker in wild-type transthyretin amyloidosis cardiomyopathy (ATTRwt-CM). [<sup>123</sup>I]-MIBG imaging evaluates cardiac sympathetic innervation but lacks volumetric activity quantification in current methods. This study aims to quantify cardiac sympathetic neuronal dysfunction in ATTRwt-CM using [<sup>123</sup>I]-MIBG SPECT/CT and correlate findings with functional and structural cardiac parameters from echocardiogram and cardiac magnetic resonance imaging (CMR).</p><p><strong>Methods: </strong>We conducted a single-center, descriptive, cross-sectional study to quantify absolute myocardial sympathetic function in ATTRwt-CM using [<sup>123</sup>I]-MIBG SPECT/CT. Retrospective reconstruction allowed for absolute tracer-uptake quantification of the left ventricle, overall and segmented, in kBq/mL, SUV and percentage of the injected dose (%ID). Echocardiography, CMR, and bone scintigraphy were performed according to clinical standards. Segmented [<sup>123</sup>I]-MIBG SPECT/CT values were correlated with global longitudinal strain (GLSS) on echocardiography, native-T1, and extracellular volume (ECV) on CMR using SPECT/CT fused with CMR.</p><p><strong>Results: </strong>Twenty-nine ATTRwt-CM patients (75.8±6.6 years, 90% male) were prospectively included. All exhibited cardiac sympathetic neuronal dysfunction, with a median late heart-to-mediastinum ratio of 1.69[1.45-1.89] and a washout rate of 22.7% (16.4-27.3%). SUV<sub>mean</sub>, SUV<sub>peak</sub>, SUV<sub>max</sub> and %ID were 1.80 ± 0.78, 3.84 ± 1.41, 4.46 ± 1.68 and 0.46 ± 0.18 respectively, correlating with semi-quantitative [<sup>123</sup>I]-MIBG measures. No correlations were found with GLSS on echocardiography or native T1 and ECV on CMR.</p><p><strong>Conclusion: </strong>The current study demonstrates the feasibility of volumetric quantification of [<sup>123</sup>I]-MIBG SPECT/CT in ATTRwt-CM. SUV<sub>mean</sub>, SUV<sub>peak,</sub> SUV<sub>max</sub> and %ID correlate with semi-quantitative measures but not with key cardiac parameters on echocardiography or CMR. This confirms the sensitivity of [<sup>123</sup>I]-MIBG SPECT/CT to different aspects of cardiac function or pathology.</p><p><strong>Trial registration: </strong>EudraCT ref. 2020-003350-72, retrospectively registered 20 March 2023. https://classic.</p><p><strong>Clinicaltrials: </strong>gov/ct2/show/NCT05776212.</p>","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":" ","pages":"102146"},"PeriodicalIF":3.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A focus on women's heart health – Raising Awareness: Women's Heart Health Day

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology

Pub Date : 2025-02-01 DOI: 10.1016/j.nuclcard.2025.102141

Panithaya Chareonthaitawee MD

引用次数: 0

‘TIDing’ over the uncertainty: Prognostic value of Transient Ischemic Dilation in Rubidium-82 PET myocardial perfusion imaging

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology

Pub Date : 2025-02-01 DOI: 10.1016/j.nuclcard.2025.102142

Christoph Rischpler

引用次数: 0

Assessing the effectiveness of tafamidis therapy in patients with transthyretin cardiac amyloidosis using 99mtechnetium pyrophosphate cardiac imaging 利用99m焦磷酸锝心脏成像技术评估经蝶雷肽心脏淀粉样变性患者接受他法米迪治疗的效果。

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology

Pub Date : 2025-02-01 DOI: 10.1016/j.nuclcard.2024.102075

Tatsuro Tasaka MD , Akiyoshi Ogimoto MD, PhD , Makoto Saito MD, PhD , Shota Koike MD , Tamami Kono MD, PhD , Kiyotaka Ohshima MD, PhD , Mareomi Hamada MD, PhD

引用次数: 0

Current practices in amyloidosis imaging with bone-avid tracer cardiac scintigraphy 使用心脏闪烁成像进行淀粉样变性成像的当前实践。

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology

Pub Date : 2025-02-01 DOI: 10.1016/j.nuclcard.2024.102078

Sarah A.M. Cuddy MD, MPH , Omar Abou-Ezzeddine MD, CM, MS , Linda P. Giering , Sharmila Dorbala MD, MPH , Jamieson M. Bourque MD, MHS, FASNC

引用次数: 0

Prognostic value of transient ischemic dilation on Rubidium-82 positron emission tomography myocardial perfusion imaging 铷-82正电子发射断层扫描心肌灌注成像中短暂缺血扩张的预后价值

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology

Pub Date : 2025-02-01 DOI: 10.1016/j.nuclcard.2024.102084

Krishna K. Patel MD, MSc , Phillip Lim MD , Poghni A. Peri-Okonny MD, MSc , Annapoorna Singh MD , A. Iain McGhie MD , Basera Sabharwal MD , Vikram Agarwal MD , Leslee J. Shaw PhD , Timothy M. Bateman MD

Background

Transient ischemic dilation (TID) of the left ventricular (LV) cavity is considered a high-risk marker in patients with abnormal single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). Stress image acquisition with rubidium-82 (⁸²Rb) PET occurs at peak stress compared to 30–60 minutes post-stress with SPECT. We aimed to evaluate the prognostic value of TID in patients undergoing ⁸²Rb PET MPI.

Methods

A total of 9878 consecutive patients with LVEF ≥40% undergoing rest/pharmacologic stress ⁸²Rb PET MPI from 2010 to 2016 were followed for a median of 3.2 years. The primary clinical outcome of cardiac death was assessed after adjusting for pre-test risk, known coronary artery disease (CAD), resting left ventricular ejection fraction (LVEF), summed stress score (SSS), LVEF reserve (LVEF-R), myocardial blood flow reserve (MBFR), and early (90-day) revascularization. Pre-specified interactions between TID and SSS were included to assess potential differences in the prognostic value of TID in patients based on perfusion.

Results

The mean age of the cohort was 69.0 (11.7) years with 56.1% being female, 49.8% having known CAD, and 27.9% having abnormal perfusion (SSS>0). There were 451 cardiac deaths. Higher TID ratios were associated with higher risk of cardiac death, even after accounting for LVEF-R and MBFR (HR per .1 unit increase = 1.25 (1.11, 1.41), P < .001). This was seen in patients with both normal (HR for TID per .1 unit increase = 1.24 (95% CI: 1.01, 1.52), P = .04) and abnormal perfusion (HR for TID per .1 unit increase = 1.14 (95% CI: 1.02, 1.28), P = .03).

Conclusions

TID on rest/stress ⁸²Rb PET MPI offers independent prognostic value in patients with both normal and abnormal perfusion independent of other risk factors in patients with LVEF ≥40%.

理由：单光子发射计算机断层扫描（SPECT）心肌灌注成像（MPI）异常患者的左心室（LV）腔一过性缺血扩张（TID）被认为是一种高危标志物。铷-82（82Rb）PET 的应激图像采集是在应激高峰期进行的，而 SPECT 是在应激后 30-60 分钟进行的。我们的目的是评估 TID 在接受 82Rb PET MPI 患者中的预后价值：2010-2016年间，共有9878名LVEF≥40%的连续患者接受了静息/药物应激82Rb PET MPI检查，随访时间中位数为3.2年。在对测试前风险、已知冠状动脉疾病（CAD）、静息左室射血分数（LVEF）、应激总分（SSS）、LVEF储备（LVEF-R）、心肌血流储备（MBFR）和早期（90天）血管再通进行调整后，对心源性死亡这一主要临床结局进行了评估。预先指定的TID比率与SSS之间的交互作用也包括在内，以评估基于灌注的TID对患者预后价值的潜在差异：组群的平均年龄为 69.0 (11.7)岁，56.1% 为女性，49.8% 有已知的 CAD，27.9% 有异常灌注（SSS>0）。即使考虑到 LVEF-R 和 MBFR（每增加 0.1 个单位的 HR =1.25 (1.11, 1.41)，p），TID 比率越高，心脏性死亡的风险也明显越高：在 LVEF >40% 的患者中，静息/压力 82RbPET MPI 的 TID 对灌注正常和异常的患者具有独立的预后价值，超过了其他风险指标。

{"title":"Prognostic value of transient ischemic dilation on Rubidium-82 positron emission tomography myocardial perfusion imaging","authors":"Krishna K. Patel MD, MSc , Phillip Lim MD , Poghni A. Peri-Okonny MD, MSc , Annapoorna Singh MD , A. Iain McGhie MD , Basera Sabharwal MD , Vikram Agarwal MD , Leslee J. Shaw PhD , Timothy M. Bateman MD","doi":"10.1016/j.nuclcard.2024.102084","DOIUrl":"10.1016/j.nuclcard.2024.102084","url":null,"abstract":"<div><h3>Background</h3><div>Transient ischemic dilation (TID) of the left ventricular (LV) cavity is considered a high-risk marker in patients with abnormal single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). Stress image acquisition with rubidium-82 (<sup>82</sup>Rb) PET occurs at peak stress compared to 30–60 minutes post-stress with SPECT. We aimed to evaluate the prognostic value of TID in patients undergoing <sup>82</sup>Rb PET MPI.</div></div><div><h3>Methods</h3><div>A total of 9878 consecutive patients with LVEF ≥40% undergoing rest/pharmacologic stress <sup>82</sup>Rb PET MPI from 2010 to 2016 were followed for a median of 3.2 years. The primary clinical outcome of cardiac death was assessed after adjusting for pre-test risk, known coronary artery disease (CAD), resting left ventricular ejection fraction (LVEF), summed stress score (SSS), LVEF reserve (LVEF-R), myocardial blood flow reserve (MBFR), and early (90-day) revascularization. Pre-specified interactions between TID and SSS were included to assess potential differences in the prognostic value of TID in patients based on perfusion.</div></div><div><h3>Results</h3><div>The mean age of the cohort was 69.0 (11.7) years with 56.1% being female, 49.8% having known CAD, and 27.9% having abnormal perfusion (SSS>0). There were 451 cardiac deaths. Higher TID ratios were associated with higher risk of cardiac death, even after accounting for LVEF-R and MBFR (HR per .1 unit increase = 1.25 (1.11, 1.41), <em>P</em> < .001). This was seen in patients with both normal (HR for TID per .1 unit increase = 1.24 (95% CI: 1.01, 1.52), <em>P</em> = .04) and abnormal perfusion (HR for TID per .1 unit increase = 1.14 (95% CI: 1.02, 1.28), <em>P</em> = .03).</div></div><div><h3>Conclusions</h3><div>TID on rest/stress <sup>82</sup>Rb PET MPI offers independent prognostic value in patients with both normal and abnormal perfusion independent of other risk factors in patients with LVEF ≥40%.</div></div>","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"44 ","pages":"Article 102084"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Amyloidosis imaging in focus: The evolution of bone-avid cardiac scintigraphy in the era of disease-modifying therapies

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology

Pub Date : 2025-02-01 DOI: 10.1016/j.nuclcard.2025.102150

Marcelo F. Di Carli MD, MASNC

引用次数: 0

Addressing motion in the estimation of myocardial blood flow with [F-18] flurpiridaz positron emission tomography

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology

Pub Date : 2025-02-01 DOI: 10.1016/j.nuclcard.2024.102123

Jonathon A. Nye, Sameer V. Tipnis

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Nuclear Cardiology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀